> ## Content Index
> Fetch the complete content index at: https://biopharmabrief.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# From Discovery to Development: How Cumberland Is Helping Build Nashville’s Life Sciences Ecosystem
- URL: https://biopharmabrief.com/from-discovery-to-development-how-cumberland-is-helping-build-nashvilles-life-sciences-ecosystem/
- Published: 2026-11-12T14:30:00.000Z
- Updated: 2026-11-17T14:35:46.000Z
- Author: Logan Mavar

### *BioPharmaBrief's Innovation in the Southeast Series*

### Nashville has long been recognized as a national center for healthcare, and when A.J. Kazimi founded Cumberland Pharmaceuticals there in 1999, he chose the city for the research strength of Vanderbilt University Medical Center, Nashville’s established healthcare industry and its entrepreneurial spirit. As Cumberland grew, academic research centers began asking the company to collaborate on earlier-stage discoveries.

That request led to the creation of Cumberland Emerging Technologies (CET), a joint initiative of Cumberland Pharmaceuticals, Vanderbilt University and the State of Tennessee. With no commercial laboratory space available in the area, CET went on to create and build the CET Life Sciences Center, an incubator providing laboratory space, equipment and infrastructure for early-stage companies.

Today, Kazimi continues to lead both Cumberland Pharmaceuticals and CET, giving him a unique perspective on the relationship between academic research, entrepreneurship and commercial drug development. We spoke with him about the evolution of Nashville’s life sciences ecosystem, what it takes to move a discovery toward commercialization, and why investors and business development executives should be paying closer attention to the opportunities emerging across the Southeast.

---

**BioPharmaBrief: You’ve built two entities in Nashville: a public pharmaceutical company and an incubator for the city’s life sciences startups. How did those two pieces come to be part of the same story?**

A.J. Kazimi:We decided to form Cumberland here in Nashville because of the presence of Vanderbilt University Medical Center and its rich history of innovative research, along with the well-established healthcare industry in this part of the country, combined with the entrepreneurial spirit of this city and its record of forming many new companies and successful ventures.

Once we got going, we were offered the opportunity to collaborate with academic research centers on earlier-stage opportunities, which was not in our original mission. To fulfill that request, we formed a second company, Cumberland Emerging Technologies, as a joint initiative between Cumberland Pharmaceuticals, Vanderbilt University and the State of Tennessee. The idea was to identify opportunities coming out of academic research centers, team with their scientists and advance those opportunities toward the market.

**BioPharmaBrief: Where does the CET Life Sciences Center fit in?**

A.J. Kazimi:To conduct that work, lab space was needed, and there was no commercial laboratory space available in this area. So we decided to start an incubator, the CET Life Sciences Center. That is where we placed our scientists and our formulation laboratories. The state contributed expensive equipment, and Vanderbilt has been providing a steady stream of projects and entrepreneurs wanting to set up their own companies.

The center was created to house our work, but also to open it up to the community and support others who are trying to build new life science companies here.

> *“The idea was to identify opportunities coming out of academic research centers, team with their scientists and advance those opportunities toward the market.”*   
> A.J. Kazimi

  
**BioPharmaBrief: When a technology comes across CET’s desk from Vanderbilt or another research center, what makes you say yes?**

A.J. Kazimi: We analyze and evaluate it against a set of key criteria that include: the scientific rationale and the data available, the path needed for approval, the proprietary position and protection through patents, and then a hard look at the commercial opportunity, the competition and whether there is a true need for the discovery in the marketplace.

We are frankly very selective about the programs we become involved with. And remember, in addition to supporting our work, we also make the Life Sciences Center available to others who want to come in and start companies around their technologies.

**BioPharmaBrief: Is there a program that shows the CET model at work?**

A.J. Kazimi:I’ll start with ifetroban. It came into Vanderbilt University through a donation from a large pharmaceutical company that discovered the compound. We reached agreement with Vanderbilt to assume responsibility for the program at Cumberland Emerging Technologies, and then handed it off to Cumberland Pharmaceuticals, which has carried it a long way since.

That’s a lot of progress on a new technology: bringing it through the university, into the company, and then doing all the work necessary to advance it towards the market.

> “Vanderbilt has been providing a steady stream of projects and entrepreneurs wanting to set up their own companies.”   
> A.J. Kazimi

**BioPharmaBrief: Nashville is known around the world for healthcare services. How is the life sciences side of the city changing, and what would most accelerate it?**

A.J. Kazimi:We feel Cumberland Pharmaceuticals is a leader in building the life sciences segment of healthcare here. There are a growing number of other companies that have either been founded here or have moved here, including some publicly traded ones. So I do see progress being made in advancing this segment of the healthcare industry.

As for what would accelerate it, there’s a secret sauce, I think, that combines attractive technologies, experienced professionals and capital. Capital has always been an important issue, especially early-stage capital. The availability of more capital for early-stage life science activities would help advance the growth of this segment here.

> “It’s a real combination of factors that a BD executive or an investor ought to understand and consider in looking at Nashville and the whole southeastern part of the country.”   
> A.J. Kazimi

  
**BioPharmaBrief: What should an investor or a business development executive outside Tennessee know about Nashville that they probably don’t?**

A.J. Kazimi:I like to say it’s one of the most successful American cities of the 21st century, and many don’t realize or recognize that. Visit and you’ll see all of the booming activity underway, in corporate relocations and investment in infrastructure, combined with the quality of life here, the reasonable cost of living and even the climate we enjoy.

It’s a real combination of factors that a BD executive or an investor ought to understand and consider in looking at Nashville and the whole southeastern part of the country.

**BioPharmaBrief: What advice would you give a scientist founder in the Southeast who is trying to take a discovery from the lab to the clinic?**

A.J. Kazimi:Just as there are criteria we use to evaluate these opportunities, scientists should be thinking through those same criteria as they develop and present their technologies and discoveries.

Make sure anything proprietary is being considered for patents. Understand what the approval pathway and requirements will be for the technology. Think about scaling it up, which includes formulation and manufacturing work which is always very important. And understand the market: how what you have could fit into what’s already available versus what’s needed. Address and position your discovery against that series of key criteria, because that is the lens a BD executive or an investor will be looking through.

---

*This interview has been edited for clarity, length and readability.*